EDTUTC-4 New YorkLog in Sign up

SCYX
SCYNEXIS, Inc.
stockNASDAQ

At CloseOct 29, 2026 3:59:53 PM EDT

3.87USD-2.025%(-0.08)133,503

Pre-marketOct 29, 2026 9:26:30 AM EDT

3.95USD0.000%(0.00)

After-hoursOct 29, 2026 4:15:30 PM EDT

3.76USD-2.842%(-0.11)

3.2500Bid4.4300Ask1.1800Spread

SCYX News

Day breaks

08:16 AM EDTSCYNEXIS reports phase 1 results for IV antifungal SCY-247 ·

Investing.com

08:00 AM EDTSCYNEXIS Completes Phase 1 Study of Intravenous SCY-247, a Novel, Triterpenoid Antifungal in Development for Treatment and Prevention of Invasive Fungal Diseases ·

GlobeNewswire Inc.

04:05 PM EDTSCYNEXIS to Feature SCY-247 in a Pipeline Presentation at IDWeek ·

GlobeNewswire Inc.

07:36 AM EDTSCYNEXIS completes phase 1 study of SCY-770 for kidney disease ·

Investing.com

07:30 AM EDTSCYNEXIS Announces Phase 1 Study Results for SCY-770, a Novel, Highly Selective, Oral Direct AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) ·

GlobeNewswire Inc.

09:28 AM EDTScynexis stock surges on $214M BARDA contract for SCY-247 ·

Investing.com

07:45 AM EDTWhy is Scynexis stock surging today? ·

Investing.com

07:36 AM EDTSCYNEXIS secures BARDA contract for antifungal development ·

Investing.com

07:30 AM EDTSCYNEXIS Awarded BARDA Contract Providing Up to $214 Million in Non-Dilutive Funding for the Development of SCY-247 ·

GlobeNewswire Inc.

08:04 AM EDTScynexis appoints Steven Burke to board of directors ·

Investing.com

08:00 AM EDTSCYNEXIS Appoints Seasoned Industry Veteran Steven K. Burke, M.D., to its Board of Directors ·

GlobeNewswire Inc.